CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 204 enrolled
Drug / intervention
Apremilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00456092
NCT00456092Phase 2Completed
CompareCT.gov

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis

Amgen·interventional·Posted Apr 4, 2007·Updated Jun 19, 2020

In Brief

A Phase 2 clinical trial evaluating Apremilast and Placebo for Psoriatic Arthritis. Completed, enrolled 204 participants across 38 sites in 5 countries.

Detailed Summary

This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesBelgium, Canada, Germany, Netherlands, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 4, 2007
Enrollment StartMar 5, 2007
Primary CompletionMay 9, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.2 years ago

Interventions

Apremilastdrug

Capsules for oral administration

Placebodrug

Capsules for oral administration